• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    EJC Skin Cancer

    EJC Skin Cancer

    JournalISSN 2772-6118eISSN 2772-6118

    年发文量

    研究主题

    论文(1156)

    排序
    1Metastatic Spiradenocarcinoma Successfully Treated with Combined Ipilimumab and Nivolumab
    Hanna Schratter, Iva Brcic, Katharina Markowski, Philipp Jakob Jost, Teresa Kränke

    Spiradenocarcinoma is a rare cutaneous adnexal malignancy with a lack of established systemic treatment options in advanced disease. We report a 65-year-old man with unresectable spiradenocarcinoma involving the regional lymph nodes, extensive perineural spread, and intracranial extension. Molecular profiling revealed a high tumor mutational burden, suggesting a combined immunotherapy with ipilimumab and nivolumab. After four cycles, complete radiological response was achieved and persisted seven months after treatment completion. This case indicates that combined CTLA-4 and PD-1 may be a promising therapeutic option for unresectable or metastatic spiradenocarcinoma.

    2026
    引用
    AI阅读
    加入学术空间
    2Immunohistochemical Predictors of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma: A Systematic Review and Narrative Synthesis
    Paulien Coenegrachts, Philip Georg Demaerel,Francesca Maria Bosisio

    Background: Cutaneous melanoma is an aggressive malignant neoplasm with a strong metastatic propensity. Sentinel lymph node biopsy is important for staging and provides prognostic information, but is associated with morbidity and detects nodal metastases in only a minority of patients. Current staging systems do not fully capture the heterogeneity of the disease. Markers predicting sentinel lymph node metastasis could improve risk stratification. Objective: To provide an overview of immunohistochemical markers studied in primary cutaneous melanoma and their association with sentinel lymph node status. Methods: PubMed, Embase, Web of Science, Scopus, and the Cochrane Library were searched on 17 May 2025. Original research articles investigating the association between immunohistochemical markers in primary cutaneous melanoma and sentinel lymph node status were included. Risk of bias was assessed using the Quality In Prognosis Studies (QUIPS) tool. Results: Fifty-two studies were included, identifying 60 immunohistochemical markers, categorized as tumor cell-related, lymphovascular cell-related, stromal cell-related, and immune cell-related. Several markers were significantly associated with sentinel lymph node status. However, many markers were evaluated in single studies, and findings across independent cohorts were often inconsistent. Risk of bias was frequently moderate to high, particularly regarding confounding and statistical analysis. Conclusion: Predicting sentinel lymph node metastasis in primary cutaneous melanoma remains challenging due to the biological complexity of the disease and limitations in the current evidence. None of the identified markers can currently be recommended for routine clinical use. Integrative approaches using advanced technologies warrant further investigation to improve risk stratification.

    2026
    引用
    AI阅读
    加入学术空间
    3Modality-specific Prognostic and Predictive Factors in Metastatic Uveal Melanoma
    Ronen Stoff,David Zahrieh,Tina J. Hieken,Anastasios Dimou,Arkadiusz Z. Dudek,Lisa A. Kottschade,Heather N. Montane,Matthew S. Block,Svetomir N. Markovic

    Introduction Treatment selection in metastatic uveal melanoma (mUM) among immune checkpoint blockade (ICB), liver-directed therapy (LDT), and tebentafusp is largely empiric, and modality-specific biomarkers are lacking. We aimed to identify modality-specific prognostic and predictive factors to inform individualized selection. Methods Retrospective cohort of 192 adults with mUM at a tertiary institution (01/2010–03/2026), contributing 500 treatment courses (194 ICB, 119 LDT, 35 tebentafusp, 27 ICB+LDT). Modality-specific bootstrap validated LASSO-Cox models and pooled gamma-frailty Cox models assessed overall survival (OS), time to next treatment (TTNT), and treatment-free interval (TFI); response rate and adverse events (AEs) were analyzed with logistic and mixed-effects models. A treatment-by-driver-oncogene interaction tested GNA11 versus GNAQ. Results Each modality had a distinct prognostic profile: ICB driven by performance status and lactate dehydrogenase (LDH); LDT by alkaline phosphatase, LDH, and time to recurrence; tebentafusp by alkaline phosphatase alone. No modality independently predicted OS, but tebentafusp extended TTNT (HR=0.29; 95% CI 0.18–0.47) and LDT extended TFI (HR=0.50; 95% CI 0.38–0.68). GNA11 mutation was predictive for LDT (interaction p = 0.004; adjusted HR=0.12; 95% CI 0.03–0.58) but not ICB. Combination ICB showed no efficacy advantage over anti-PD-1 monotherapy but greater grade ≥ 3 toxicity (odds ratio 5.60; P = 0.003). Discussion Disease biology, rather than modality, is the primary survival determinant, yet each modality carries a distinct prognostic profile. GNA11 is a candidate predictive biomarker for LDT-the first modality-specific genomic biomarker in mUM. Conclusions Modality-specific profiling may enable personalized selection. Combination ICB should not be the default given harm without benefit; prospective GNA11-LDT validation is the priority.

    2026
    引用
    AI阅读
    加入学术空间
    4Ten-year Outcomes after Initial Response to Immune Checkpoint Inhibitors in Patients with Advanced Merkel Cell Carcinoma
    Hemant Khandelia,Daniel S. Hippe,Paul Nghiem,Shailender Bhatia

    Background Immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced Merkel cell carcinoma (MCC) with response rates up to 60% in the 3 pivotal trials (KEYNOTE-017, JAVELIN Merkel-200 and CheckMate-358). However, long-term outcomes, including response durability and survival, remain unclear due to limited follow-up periods in these trials. Methods We conducted a single-center retrospective study of 30 patients with advanced MCC who received ICIs through one of these 3 trials. In patients with an initial response to trial ICI, we analyzed the duration of response (DOR) and MCC-specific survival (MSS). For patients who progressed after their initial response, salvage therapies and subsequent outcomes were evaluated. Results Twenty of 30 patients (67%) experienced an objective response to the trial ICI regimen (9 – pembrolizumab, 5 – avelumab, 3 – nivolumab and 3 – ipilimumab plus nivolumab). In this cohort of 20 responders, median follow-up was 10.8 years [range, 1.8–11.1]. Median DOR was 6.1 years [95% CI, 2.8–not reached]. Ten patients (50%) remained progression-free. Among the 10 progressing patients, 3 achieved durable disease control with salvage therapies. The 10-year MSS estimate was 70% [95% CI, 49–88%]. There were 7 deaths total (6 MCC-related and 1 from non-MCC comorbidity). Conclusions ICI-induced responses in patients with advanced MCC can be highly durable, extending beyond 10 years in ~50% of responders and leading to long-term survivorship. However, acquired resistance to ICIs is not infrequent, warranting long-term surveillance. Salvage therapies can provide prolonged benefit in a subset of progressing patients.

    2026
    引用
    AI阅读
    加入学术空间
    5Influence of Dosage and Therapeutic Interval on the Incidence of Severe Side Effects of Immunotherapy with PD-1 Inhibitors in Malignant Melanoma
    Rebecca Diehl, Marlon Grodd, Valentina Bieneck, Adriana Lazarou,Frank Meiss,Saskia Lehr, David Rafei

    Introduction Immune checkpoint inhibitors targeting PD-1 are approved for malignant melanoma using two dosing regimens, with extended-interval fixed-dose schedules approved primarily based on pharmacokinetic modelling. Real-world data comparing dose-dependent immune-related adverse event (irAE) profiles across regimens and agents remain scarce. Methods In this monocentric retrospective analysis, patients with malignant melanoma receiving PD-1 inhibitor monotherapy between 2014 and 2025 were investigated for irAEs, stratified by dosing regimen; events were graded per CTCAE version 5.0. To account for the competing risk of death, an extended illness-death model was applied generating stacked probability plots for each dosing subgroup. Results A total of 499 patients (nivolumab, n = 210; pembrolizumab, n = 289) were included. Any-grade irAEs occurred in 41.4–58.3% of pembrolizumab-treated and 32.1–43.9% of nivolumab-treated patients, with incidence increasing with dose in both agents. Grade 3/4 irAEs were most frequent in the highest fixed-dose subgroups: 13.9% (pembrolizumab 400 mg) and 11.4% (nivolumab 480 mg). Stacked probability plots, accounting for death and treatment discontinuation as competing risks, showed that the highest fixed-dose regimens had the steepest increase in irAE-related outcomes. Conclusion In this real-world cohort, both pembrolizumab and nivolumab showed a numerical trend toward higher irAE incidence and severity with increasing dose, most notably in the pembrolizumab 400 mg regimen. Given the limited subgroup sizes, these findings should be regarded as hypothesis-generating rather than confirmatory. Larger prospective, multicentre studies are needed to validate this dose-dependent signal, ideally incorporating multistate models to account for competing risks.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1156 篇论文

    高被引作者

    作者引用发文
    Simone Ribero127
    Pakavarin Louphrasitthiphol111
    Jana Travnickova111
    Chris Schofield111
    Owen Sansom111
    Jair Marques111
    Robert Illingworth111
    Ulrike Leiter1113
    Pablo García-Martínez111
    Joseph A. Marsh111

    高产作者

    作者引用发文
    Dirk Schadendorf121
    Susana Puig220
    Celeste Lebbé116
    Josep Malvehy415
    Paolo A. Ascierto814
    Ulrike Leiter1113
    Reinhard Dummer012
    F. Meier012
    Veronique Del Marmol512
    Ralf Gutzmer611

    相关期刊

    暂无数据
    暂无数据